ELI LILLY AND COMPANY |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 146.7 BRL | -0.46% |
|
+4.41% | +57.03% |
| 06-06 | US FDA panel to vote on data, risk profile of Lilly Alzheimer's drug | RE |
| 06-06 | Novo Nordisk braces for generic challenge to Ozempic, Wegovy in China | RE |
| Sales 2024 * | 42.98B 226B 58.73B | Sales 2025 * | 52.62B 277B 71.91B | Capitalization | 754B 3,964B 1,030B |
|---|---|---|---|---|---|
| Net income 2024 * | 11.93B 62.73B 16.3B | Net income 2025 * | 16.55B 87.03B 22.62B | EV / Sales 2024 * | 18 x |
| Net Debt 2024 * | 18.07B 95.01B 24.69B | Net Debt 2025 * | 15B 78.85B 20.49B | EV / Sales 2025 * | 14.6 x |
| P/E ratio 2024 * |
62.6
x | P/E ratio 2025 * |
45.1
x | Employees | 43,000 |
| Yield 2024 * |
0.62% | Yield 2025 * |
0.72% | Free-Float | 99.8% |
More Fundamentals
* Assessed data
More news
Latest transcript on Eli Lilly and Company
More recommendations
More press releases
More news
| 1 day | -0.46% | ||
| 1 week | +4.41% | ||
| Current month | +0.56% | ||
| 1 month | +13.03% | ||
| 3 months | +14.10% | ||
| 6 months | +51.69% | ||
| Current year | +57.03% |
1 week
143.51
148.95
1 month
128.64148.95
Current year
94.16148.95
1 year
69.46148.95
3 years
36.62148.95
5 years
13.56148.95
10 years
4.39148.95
| Managers | Title | Age | Since |
|---|---|---|---|
David Ricks
CEO | Chief Executive Officer | 56 | 95-12-31 |
Ruth Gimeno
PSD | President | - | - |
David Hyman
CTO | Chief Tech/Sci/R&D Officer | - | 23-10-15 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
| Director/Board Member | 63 | 21-01-24 | |
Ralph Alvarez
BRD | Director/Board Member | 68 | 09-03-31 |
Jon Fyrwald
BRD | Director/Board Member | 63 | 04-12-31 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-06-06 | 146.7 | -0.46% | 3,370 |
| 24-06-05 | 147.4 | -0.13% | 9,358 |
| 24-06-04 | 147.6 | +1.09% | 8,291 |
| 24-06-03 | 146 | +0.06% | 16,290 |
| 24-05-31 | 145.9 | +3.83% | 6,855 |
Delayed Quote Sao Paulo, June 06, 2024 at 03:50 pm
More quotes
Eli Lilly and Company is one of the world's leading pharmaceutical groups. Net sales break down by therapeutic field as follows:
- endocrinology (57.7%): products for treating osteoporosis, diabetes, and growth problems;
- oncology (19.5%);
- immunology diseases (11.1%);
- neurology (8.4%): primarily drugs used in treating depression and schizophrenia;
- other (3.3%).
Net sales are distributed geographically as follows: the United States (63.9%), Europe (18.1%), Japan (4.9%), China (4.5%) and other (8.6%).
Sector
Pharmaceuticals
Calendar
Related indices
Trading Rating
Investor Rating
ESG Refinitiv
Sell
Buy
Mean consensus
BUY
Number of Analysts
28
Last Close Price
837.3
USD
Average target price
852.5
USD
Spread / Average Target
+1.82%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +39.42% | 605B | |
| -6.58% | 351B | |
| +19.72% | 328B | |
| +8.78% | 292B | |
| +11.92% | 216B | |
| -2.62% | 214B | |
| +0.03% | 167B | |
| +6.13% | 165B | |
| +1.39% | 123B |
- Stock Market
- Equities
- LLY Stock
- LILY34 Stock
